SCHEMBL6891733

SCHEMBL6891733

COC(=O)c1cccc2c1c1c(O)cc(-c3ccccc3)cc1n2Cc1ccccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
GAA P10253 1/20 0.43
PLA2G2A P14555 1/20 0.43
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HTT P42858 2/20 0.40
HPGD P15428 1/20 0.40
HIF1A Q16665 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
THRB P10828 2/20 0.39
TSHR P16473 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6897905 0.92 DRD2 (0.43) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6895052 0.90 PLA2G1B (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6894747 0.90 PLA2G2A (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6892544 0.89 MAPT (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6894916 0.89 MAPT (0.45) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6894204 0.89 L3MBTL1 (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6894500 0.89 PTGDR2 (0.39) KDM4EMEN1KMT2AALDH1A1NPSR1
SCHEMBL6777361 0.88 PLA2G2A (0.46) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6694644 0.88 AR (0.45) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6689180 0.88 LMNA (0.47) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed